Posted by shutah on February 19, 2011
Surely, one of the proudest moment’s in Bob Fiddaman’s quest for justice in the eternal fight against SSRI’s .
As Bob writes in his blog “What could piss off GlaxoSmithKline more than Bob Fiddaman getting an award for basically highlighting their dark history?”
Way to go Fiddy!!!!!!
[Click the pic to read the full story]
Posted in Blogroll, Depression, GlaxoSmithKline, GSK, Health, Paroxetine, Paxil, Seroxat, SSRIs | Tagged: Antidepressants, Big Pharma, GlaxoSmithKline, GSK, psychiatry, SSRI, SSRIs | 1 Comment »
Posted by shutah on January 22, 2011
More than 60 people in Britain who say they have become hooked on the anti-depressant Seroxat – a drug in the Prozac class – are exploring the possibility of legal action against the pharmaceutical company which they claim failed to warn doctors that that it could create dependency.
Two firms of solicitors say they already have between 30 and 40 cases each. The people have come forward following news of a legal case in the US in which 35 people allege they suffered severe side-effects when they tried to stop taking the drug.
The Los Angeles law firm Baum, Hedlund, Aristei, Guilford and Schiavo – which filed its action against the British manufacturers GlaxoSmithKline in September – has since had more than 2,000 calls from people to tell of their addiction to the drug, which is known in the US as Paxil. The side-effects they suffer when they try to stop taking the tablets, include jolting pains in the head, vertigo, loss of coordination, abdominal discomfort, agitation and confusion.
The US lawyers have asked GSK to set up treatment centres to help people attempting to withdraw from Paxil/Seroxat. GSK say there is no reliable scientific evidence that the drug causes addiction or dependency.
The British solicitors, Ross & Co, based in the Wirral, and Hugh James Ford Simey of Cardiff, have been receiving calls from people who did not realise that others had suffered the same symptoms when they tried to cut down and come off the drug.
“We have been contacted by 30 to 40 people, most of whom have startlingly similar tales to tell of being put on the drug and being taken off it, and then going back on,” said Mark Harvey of Hugh James Ford Simey.
Mr Harvey said most people are told by the doctor that their problems are the symptoms of their depression re-appearing and do not suspect that the drug might be to blame. “This does have the smell of something that is a problem,” he said. “The patient information sheet says it is not addictive twice.”
Graham Ross, of Ross & Co, thinks that there is a good potential case against the manufacturers. “So far as evidence of dependency is concerned, that is pretty strong,” he said.
“I feel we can prove that. Failure to ensure that GPs are aware of that risk and therefore warn patients accordingly – there is plenty of evidence that they are not doing that.”
But group actions face particular problems in Britain. Attempts to litigate against the makers of benzodiazapines – including Valium, Librium and Ativan, which were also said not to be addictive when they were launched – collapsed because the legal aid granted to the claimants was used up in the lengthy investigations of the cases demanded by the companies before the action reached court.
Posted in GlaxoSmithKline, GSK, Paroxetine, Paxil, Seroxat, Seroxat Legal, SSRIs, Withdrawal | Tagged: Antidepressants, GlaxoSmithKline, GSK, Litigation, Paroxetine, Paxil, Seroxat, SSRI, Withdrawal | 1 Comment »
Posted by shutah on January 18, 2011
Drugs. 1991 Feb;41(2):225-53.
Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
Dechant KL, Clissold SP.
Adis Drug Information Services, Auckland, New Zealand.
Paroxetine is a potent and selective inhibitor of the neuronal reuptake of serotonin, thereby facilitating serotoninergic transmission; this action appears to account for the antidepressant activity observed with this drug. A mean terminal elimination half-life of approximately 24 hours permits once daily administration.
Results of short term clinical trials have shown paroxetine to be significantly superior to placebo, and comparable to amitriptyline, clomipramine, imipramine, dothiepin and mianserin in relieving symptoms associated with major depressive disorders.
Paroxetine has shown some preliminary promise in the treatment of depressive illness resistant to tricyclic antidepressant therapy but further studies are required before any conclusions can be drawn.
Paroxetine in therapeutic doses has been very well tolerated, and the favourable tolerability profile of this agent appears to be its primary advantage over traditional antidepressant agents.
Paroxetine causes minimal anticholinergic-type adverse effects, and unlike tricyclic antidepressants, it does not precipitate cardiovascular effects or provoke cardiac conduction disturbances. Nausea has been the most frequently reported adverse event during short term use of paroxetine, but it is generally mild and transient and subsides with continued use. With longer term use headache, sweating and constipation were the most frequently reported side effects but the incidence rate was not significantly different from that noted for comparator antidepressants. Furthermore, the frequency of withdrawal due to adverse effects is less with paroxetine than with tricyclic antidepressant agents.
Overall, available data appear to indicate that while the efficacy of paroxetine is similar to that of traditional antidepressant drugs, the newer agent possesses much improved tolerability.
In addition, the wide therapeutic index of paroxetine may be beneficial when treating patients with an increased risk of suicide.
Thus, paroxetine clearly looks to become a valuable addition to the range of drugs currently available to treat depressive illness. Future research may help to further define the relative place of this newer agent in antidepressant therapy and determine how its overall therapeutic efficacy compares with that of other related antidepressant agents such as fluoxetine.
Posted in Paroxetine, Paxil, Seroxat, SSRIs | Tagged: Paroxetine, Paxil, Seroxat | Leave a Comment »
Posted by shutah on January 18, 2011
Well well well … this is something I didn’t know about Seroxat, and it explains quite a lot for me personally!!!!
Short report from Br. J. clin. Pharmac. (1986), 22, 97-99
Posted in Blogroll, Health, Paroxetine, Paxil, Seroxat, SSRIs | Tagged: Paxil, Seroxat, Sleep, SSRIs | Leave a Comment »
Posted by shutah on January 16, 2011
Whilst a technical piece of information, this document highlights the differences between the various SSRIs .
“The half-life of paroxetine is a function of its plasma drug level. Following a single 20 mg dose, paroxetine has a half-life of 10 hours (Table 6.4). Paroxetine does not reach a half-life of 20 hours until steady-state has been reached on 20 mg/day (Table 6.4) because paroxetine inhibits CYP 2D6, which is the CYP enzyme responsible for its biotransformation. When paroxetine levels fall after this drug is discontinued, its clearance rate increases as the inhibition of the enzyme is decreased. Thus, paroxetine and fluvoxamine are more quickly cleared from the body than the other SSRIs. “
Posted in Paxil, Seroxat, SSRIs, Withdrawal | Tagged: Paroxetine, Paxil, Seroxat, SSRIs | Leave a Comment »